Clinical trials: Cancer Progression
Adenocarcinoma of Prostate, Progression of Prostate Cancer
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
The objective of this study is to assess the effect of neoadjuvant cabazitaxel and pelvic radiotherapy in combination with androgen deprivation therapy (ADT)-radiotherapy on clinical progression-free survival in patients with…
- Trial name
- PEACE2 (NCT01952223)
- Testing
- Cabazitaxel, Pelvic radiotherapy, prostate radiotherapy
- Where
- France
- Volunteers
- 761 people
- Sponsor
- UNICANCER
Peri-Implantitis, Bleeding of Subgingival Space
Incidence of Bleeding on Probing as an Indicator of Peri-Implant Disease Progression
The primary goal of the present prospective cohort study is to evaluate the effect of varying incidences of BOP at implant sites across 15 months of maintenance visits on the probability of peri-implant disease progression.
- Trial name
- BOP (NCT06033859)
- Testing
- Clinical measurements, Radiographic measurement, Dental prophylaxis or maintenance
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Indolent B-cell NHL
A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.
To compare the efficacy of bendamustine against treatment of physician's choice on progression-free survival in subjects with indolent B-cell NHL.
- Trial name
- ROBIN (NCT01289223)
- Testing
- Bendamustine IV, Treatment of Physicians Choice
- Where
- 3 sites in Australia, Slovakia
- Volunteers
- 88 people
- Sponsor
- Mundipharma Research Limited
Colorectal Cancer
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
This 2-arm study was designed to evaluate the efficacy and safety of 2 treatment regimens of Xeloda and Avastin, with either irinotecan or oxaliplatin administered for the first 12 cycles, as first line treatment in patients with…
- Trial name
- NCT00642603
- Testing
- capecitabine [Xeloda], bevacizumab [Avastin], oxaliplatin
- Where
- 76 sites in United States
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III
ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1
The goal of this clinical trial is to learn if ASTX727 can be combined with retifanlimab to treat Merkel cell cancer. It will also learn about the safety of combining these drugs.
- Conditions
- Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III, Merkel Cell Carcinoma, Stage IV
- Trial name
- NCT07472322
- Testing
- ASTX727 + retifanlimab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Wisconsin, Madison
Diabetes, Critical Limb Ischemia
Diabetic Foot and Vascular Progenitor Cells
Type of Study: Pilot Study monocenter Study Duration: 18 months Subject Participation Duration: The patients are enrolled for the time of the blood withdrawl. Follow up visit will be after 12 months from the enrollement.
- Trial name
- NCT01269580
- Where
- Italy
- Volunteers
- 122 people
- Sponsor
- IRCCS Multimedica
Hepatitis B, Chronic
Relationship Between MAFLD and Liver Fibrosis Progression in Patients With Chronic Hepatitis B: a Multicenter Retrospective Cohort Study
This multicenter retrospective study aims to study the association between the presence of MAFLD and change in liver stiffness over time in untreated and treated patients with chronic hepatitis B
- Trial name
- MAFLD-HBV 1 (NCT05708560)
- Where
- 3 sites in Netherlands
- Volunteers
- 800 people
- Sponsor
- Erasmus Medical Center
Advanced Biliary Tract Carcinoma
Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma
The prognosis for unresectable and metastatic biliary tract cancers (BTCs) including cholangiocarcinoma is poor with first line gemcitabine and cisplatin offering a median overall survival of 11.7 months.
- Trial name
- NCT04550624
- Testing
- Pembrolizumab Injection [Keytruda], Lenvatinib Mesylate
- Where
- 2 sites in China
- Volunteers
- 27 people
- Sponsor
- Shanghai Jiahui International Hospital
Cholestasis, Progressive Familial Intrahepatic 3
Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION
Cholangiocarcinoma (CCK) is a rare tumor (2000 new cases/year in France) with very poor prognosis (overall survival < 3% at 5 years).
- Trial name
- CHOLANGIOSIR (NCT01383746)
- Testing
- Yttrium microsphere injection
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Prostate Cancer, Castration-Resistant Prostate Cancer
AI Multimodal Model for Predicting CRPC Progression Risk
This study aims to develop an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing castration-resistant prostate cancer (CRPC), a more severe form of the disease.
- Trial name
- AI-MM_CPRC (NCT07658573)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Guangxi Medical University
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as…
- Trial name
- NCT06095583
- Testing
- Tifcemalimab injection, toripalimab injection
- Where
- 76 sites in China, Georgia and 4 more
- Volunteers
- 756 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Myopia
Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)
Myopia, or shortsightedness, is a multifactorial disorder, governed by environmental and genetic factors. Myopia is the most common ocular disorder worldwide with an increasing prevalence over the past few decades and affecting…
- Trial name
- MODERATO (NCT07028827)
- Testing
- 0.05% atropine eye drops, 0.025% atropine eye drops
- Where
- 11 sites in Albania, Italy and 3 more
- Volunteers
- 234 people
- Sponsor
- Ocus Innovation Ireland Limited
Coronary Artery Disease, Non-Obstructive Coronary Atherosclerosis
VIsualization of Coronary Artery Disease for Modification of RISK Factors
The VICAD-RISK study assesses if visualization of coronary CT angiography (CTA) images in participants with non-obstructive coronary artery disease will improve LDL lowering, reduce reporting of side effects by cholesterol…
- Trial name
- VICAD-RISK (NCT06413641)
- Testing
- Follow up at general practice, Consultation, Visualization of CTA images
- Where
- 5 sites in Denmark
- Volunteers
- 273 people
- Sponsor
- Aarhus University Hospital
Brain Metastases
Evaluation of Brain Metastases Treated With Stereotactic Radiotherapy Using Dynamic [18F]FDG PET
The purpose of this study is to evaluate the clinical usefulness of dynamic [18F]FDG PET imaging in assessing brain metastasis post stereotactic radiotherapy to separate true progression from the treatment-related changes.
- Trial name
- NCT06511323
- Testing
- dynamic [18-FDG PET] scan post stereotactic radiation for brain metastases
- Volunteers
- 70 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Renal Insufficiency, Chronic, Hyperkalemia
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC), as adjunct to ACEi/ARB therapy (lisinopril or valsartan), on slowing CKD progression (assessed as the reduction in participant's…
- Trial name
- STABILIZE-CKD (NCT05056727)
- Testing
- Sodium Zirconium Cyclosilicate (SZC), Lisinopril, Valsartan
- Where
- 276 sites in United States, Argentina and 19 more
- Volunteers
- 1,112 people
- Sponsor
- AstraZeneca
Melanoma
Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.
Patients with locally advanced melanoma are at high risk for recurrence following surgical treatment. More patients with stage IV melanoma remain in complete remission following systemic therapy.
- Trial name
- DW-MRi (NCT02907827)
- Testing
- follow up DW MRI
- Where
- 2 sites in Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
This is a retrospective observational, open label study to evaluate and prospectively validate in a blind manner the accuracy of predicting treatment outcomes by PrediCare in individual patients with Non-Small Cell Lung Cancer…
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Prostate Cancer, Breast Cancer
- Trial name
- NCT02577627
- Testing
- PrediCare
- Where
- Israel
- Volunteers
- 5,000 people
- Sponsor
- Optimata Ltd.
X-linked Adrenoleukodystrophy
Disease Progression in Women With X-linked Adrenoleukodystrophy
Observational, single-site prospective and minimally interventional study in women with X-linked adrenoleukodystrophy (ALD), conducted in France.
- Trial name
- NCT06178120
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Minoryx Therapeutics, S.L.
Prostate Cancer
TherApeutics in Early ProState Cancer (TAPS02)
This is a phase 2, randomised, multicentre, double-blind, placebo-controlled trial investigating the use of short term androgen deprivation therapy in the form of apalutamide (Erleada) in men on active surveillance for prostate…
- Trial name
- NCT05191680
- Testing
- Apalutamide Oral Tablet [Erleada]
- Where
- 6 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Cardiogenic Shock
Awake Axillary Impella 5.5 Placement - A Feasibility Trial
The Abiomed Impella 5.5 is a surgically placed temporary mechanical support device used in patients in cardiogenic shock. The investigators propose using regional anesthesia (3 separate peripheral nerve blocks) to facilitate…
- Trial name
- NCT05782491
- Testing
- Interscalene Block, PECS II Block, Superficial Cervical Plexus Block
- Where
- 2 sites in United States
- Sponsor
- University of Pennsylvania
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.